STOCK TITAN

Aprea Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Aprea Therapeutics (Nasdaq: APRE), a biopharmaceutical company, is set to present a corporate update at the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021, at 2:50 p.m. ET. The presentation will provide insights into the company's innovative cancer therapeutics aimed at reactivating the p53 tumor suppressor protein. A live webcast will be available on the company's website. Aprea's lead product candidate, eprenetapopt (APR-246), is in clinical development and has received various FDA designations for myelodysplastic syndromes and acute myeloid leukemia.

Positive
  • None.
Negative
  • None.

BOSTON, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schade, Chairman and Chief Executive Officer, will present a corporate update at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 2:50 p.m. ET.

A live webcast of the presentation can be accessed under the "Events Calendar" in the Investors section of the Aprea website at Link.

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company’s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors. Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for myelodysplastic syndromes (MDS), Fast Track designation from the FDA for acute myeloid leukemia (AML), and Orphan Drug designation from the European Commission for MDS and AML. APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration. For more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

Forward-Looking Statement

Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our study analyses, clinical trials, regulatory submissions and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward looking statements are subject to risks and uncertainties including risks related to the success and timing of our clinical trials or other studies, risks associated with the coronavirus pandemic and the other risks set forth in our filings with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Source: Aprea Therapeutics, Inc.

Corporate Contacts:

Scott M. Coiante

Sr. Vice President and Chief Financial Officer

617-463-9385

Gregory A. Korbel

Vice President of Business Development

617-463-9385


FAQ

What is Aprea Therapeutics presenting at the J.P. Morgan Healthcare Conference?

Aprea Therapeutics will present a corporate update highlighting their cancer therapeutics at the 39th Annual J.P. Morgan Healthcare Conference.

When is Aprea Therapeutics' presentation at the J.P. Morgan Healthcare Conference?

The presentation is scheduled for January 12, 2021, at 2:50 p.m. ET.

Where can I watch Aprea Therapeutics' presentation?

A live webcast of the presentation can be accessed under the 'Events Calendar' in the Investors section of the Aprea website.

What is the lead product candidate of Aprea Therapeutics?

Aprea's lead product candidate is eprenetapopt (APR-246), which is in clinical development for hematologic malignancies and solid tumors.

What designations has eprenetapopt received from the FDA?

Eprenetapopt has received Breakthrough Therapy, Orphan Drug, and Fast Track designations for myelodysplastic syndromes and Fast Track for acute myeloid leukemia.

Aprea Therapeutics, Inc.

NASDAQ:APRE

APRE Rankings

APRE Latest News

APRE Stock Data

19.55M
5.43M
11.75%
43.85%
0.28%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
DOYLESTOWN